Executive Summary: Confronting Major Safety Issues of the 21st Century (June 2008)

The Drug Safety Executive Council (DSEC), organized by CHA, brought together safety experts from across the biopharmaceutical industry at the inaugural DSEC Member Retreat, Confronting Major Safety Issues of the 21st Century. The meeting was held June 10-11, 2008 in Philadelphia.

Summit participants included senior safety executives from various large biopharmaceutical companies including Amgen, Astellas, AstraZeneca, Bayer Healthcare, Biogen Idec, Boehringer-Ingelheim, Genzyme, GlazoSmithKline, Pfizer, Procter & Gamble, Roche, Shire, Takeda, UCB and Wyeth. Also participating a number of senior executives from other industry organizations with a vested interest in drug safety. These included Baxter Healthcare, Cellumen, iCardiac, the National Institutes of Health (NIH), and the Critical Path Institute, among others. The summit agenda was crafted in close cooperation with the DSEC Advisory Board, led by Dr Jack Reynolds, and representatives from Eli Lilly, F Hoffman-La Roche, Johnson & Johnson, Sanofi-Aventis, and Schering-Plough.

Register to access the Executive Summary using the form below.